These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 9524622)

  • 1. [3D-Ct-planned interstitial HDR brachytherapy + percutaneous irradiation and chemotherapy in inoperable pancreatic carcinoma. Methods and clinical outcome].
    Pfreundner L; Baier K; Schwab F; Willner J; Bratengeier K; Flentje M; Feustel H; Fuchs KH
    Strahlenther Onkol; 1998 Mar; 174(3):133-41. PubMed ID: 9524622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Definitive radiotherapy based on HDR brachytherapy with iridium 192 in uterine cervix carcinoma: report on the Vienna University Hospital findings (1993-1997) compared to the preceding period in the context of ICRU 38 recommendations.
    Pötter R; Knocke TH; Fellner C; Baldass M; Reinthaller A; Kucera H
    Cancer Radiother; 2000; 4(2):159-72. PubMed ID: 10812362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined isodose curves of high-dose rate interstitial brachytherapy with external-beam radiation therapy in pancreatic carcinoma.
    Warszawski N; Pfreundner L; Bratengeier K; Bohndorf W; Feustel H
    Strahlenther Onkol; 1992 Sep; 168(9):552-7. PubMed ID: 1384154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: results of a feasibility study.
    Prott FJ; Schönekaes K; Preusser P; Ostkamp K; Wagner W; Micke O; Pötter R; Sulkowski U; Rübe C; Berns T; Willich N
    Br J Cancer; 1997; 75(4):597-601. PubMed ID: 9052417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High dose rate intraoperative radiation therapy (HDR-IORT) as part of the management strategy for locally advanced primary and recurrent rectal cancer.
    Harrison LB; Minsky BD; Enker WE; Mychalczak B; Guillem J; Paty PB; Anderson L; White C; Cohen AM
    Int J Radiat Oncol Biol Phys; 1998 Sep; 42(2):325-30. PubMed ID: 9788411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I/II study of external beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 92-07): preliminary toxicity report.
    Gaspar LE; Qian C; Kocha WI; Coia LR; Herskovic A; Graham M
    Int J Radiat Oncol Biol Phys; 1997 Feb; 37(3):593-9. PubMed ID: 9112458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma.
    Keene KS; Rich TA; Penberthy DR; Shepard RC; Adams R; Jones RS
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):97-103. PubMed ID: 15850908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer.
    Roddiger SJ; Kolotas C; Filipowicz I; Kurek R; Kuner RP; Martin T; Baltas D; Rogge B; Kontova M; Hoffmann G; Pollow B; Zamboglou N
    Strahlenther Onkol; 2006 Jan; 182(1):22-9. PubMed ID: 16404517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palladium-103: a new radioactive source in the treatment of unresectable carcinoma of the pancreas: a phase I-II study.
    Nori D; Merimsky O; Osian AD; Heffernan M; Cortes E; Turner JW
    J Surg Oncol; 1996 Apr; 61(4):300-5. PubMed ID: 8628003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple-tandem high-dose-rate brachytherapy for early-stage medically inoperable endometrial cancer: Initial report on acute toxicity and dosimetric comparison to stereotactic body radiation therapy.
    Kauffmann G; Wu T; Al-Hallaq H; Hasan Y
    Brachytherapy; 2017; 16(1):141-146. PubMed ID: 27866953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraoperative and conformal external-beam radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic carcinoma.
    Furuse J; Kinoshita T; Kawashima M; Ishii H; Nagase M; Konishi M; Nakagohri T; Inoue K; Ogino T; Ikeda H; Maru Y; Yoshino M
    Cancer; 2003 Mar; 97(5):1346-52. PubMed ID: 12599244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CT-guided high-dose-rate brachytherapy in the interdisciplinary treatment of patients with liver metastases of pancreatic cancer.
    Wieners G; Schippers AC; Collettini F; Schnapauff D; Hamm B; Wust P; Riess H; Gebauer B
    Hepatobiliary Pancreat Dis Int; 2015 Oct; 14(5):530-8. PubMed ID: 26459730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
    Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
    Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twice-daily fractionation of external irradiation with brachytherapy and chemotherapy in carcinoma of the cervix with positive para-aortic lymph nodes: Phase II study of the Radiation Therapy Oncology Group 92-10.
    Grigsby PW; Lu JD; Mutch DG; Kim RY; Eifel PJ
    Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):817-22. PubMed ID: 9652843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-fluorouracil-based chemoradiation in unresectable pancreatic carcinoma: Phase I-II dose-escalation study.
    Morganti AG; Valentini V; Macchia G; Mattiucci GC; Costamagna G; Deodato F; Smaniotto D; Luzi S; Balducci M; Barbi S; Perri V; Trodella L; Cellini N
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1454-60. PubMed ID: 15275732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of a T1 cancer of the pancreatic head with high dose rate brachytherapy and external radiotherapy.
    Takácsi-Nagy Z; Varga J; Poller I; Fodor J; Polgár C; Petrányi A; Major T; Németh G
    Hepatogastroenterology; 2002; 49(45):844-6. PubMed ID: 12064004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.
    Abrams RA; Grochow LB; Chakravarthy A; Sohn TA; Zahurak ML; Haulk TL; Ord S; Hruban RH; Lillemoe KD; Pitt HA; Cameron JL; Yeo CJ
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1039-46. PubMed ID: 10421536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of unresectable pancreatic carcinoma by intraluminal brachytherapy in the duct of Wirsung.
    Mutignani M; Shah SK; Morganti AG; Perri V; Macchia G; Costamagna G
    Endoscopy; 2002 Jul; 34(7):555-9. PubMed ID: 12170409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose-rate brachytherapy boost following concurrent chemoradiotherapy for esophageal carcinoma.
    Yorozu A; Dokiya T; Oki Y
    Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):271-5. PubMed ID: 10487545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.